The DOI matches its Crossref record.
Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy.
Open accessAbstract
RATIONALE: Advanced glycosylation end products (AGEs) may play an important role in the development of diabetic vascular sequelae. An AGE cross-link, pentosidine, is a sensitive and specific marker for tissue levels of AGEs. OBJECTIVES: To evaluate the role of AGEs in the development of diabetic nephropathy and retinopathy, we studied pentosidine levels and the clinical characteristics of 48 subjects with insulin-dependent diabetes mellitus. Diabetic nephropathy was classified as normal, microalbuminuria, or gross proteinuria, and retinopathy was graded as none, background, or proliferative. NEWLY OBSERVED FINDINGS: Significant elevation of pentosidine (P = 0.025) was found in subjects with microalbuminuria or gross proteinuria (73.03 +/- 9.47 vs 76.46 +/- 6.37 pmol/mg col) when compared with normal (56.96 +/- 3.26 pmol/mg col). Multivariate analysis to correct for age, duration of diabetes, and gender did not modify the results. Elevated pentosidine levels were also found in those with proliferative when compared with those with background retinopathy (75.86 +/- 5.66 vs 60.42 +/- 5.98 pmol/mg col) (P < 0.05). CONCLUSIONS: Microalbuminuria is associated with elevated levels of pentosidine similar to those found in overt diabetic nephropathy suggesting that elevated AGE levels are already present during the earliest detectable phase of diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
BASTA, G. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.05.001 · Cited by 999
Schmidt, A. M., Yan, S. D., Wautier, J.-L., & Stern, D. (1999) · Circulation Research · doi:10.1161/01.res.84.5.489 · Cited by 791
Schleicher, E. D., Wagner, E., & Nerlich, A. G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119180 · Cited by 714
Schmidt, A. M., Hori, O., Brett, J., Yan, S. D., Wautier, J. L., & Stern, D. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.10.1521 · Cited by 635
Wells-Knecht, K. J., Zyzak, D. V., Litchfield, J. E., Thorpe, S. R., & Baynes, J. W. (1995) · Biochemistry · doi:10.1021/bi00011a027 · Cited by 595
Reddy, S., Bichler, J., Wells-Knecht, K. J., Thorpe, S. R., & Baynes, J. W. (1995) · Biochemistry · doi:10.1021/bi00034a021 · Cited by 524
Yan, S. F., Ramasamy, R., Naka, Y., & Schmidt, A. M. (2003) · Circulation Research · doi:10.1161/01.res.0000103862.26506.3d · Cited by 513
How hyperglycemia promotes atherosclerosis: molecular mechanisms
Aronson, D., & Rayfield, E. J. (2002) · Cardiovascular Diabetology · doi:10.1186/1475-2840-1-1 · Cited by 504
Horie, K., Miyata, T., Maeda, K., Miyata, S., Sugiyama, S., Sakai, H., van Ypersole de Strihou, C., Monnier, V. M., Witztum, J. L., & Kurokawa, K. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119853 · Cited by 433
Genuth, S., Sun, W., Cleary, P., Sell, D. R., Dahms, W., Malone, J., Sivitz, W., Monnier, V. M., & for the DCCT Skin Collagen Ancillary Study Group (2005) · Diabetes · doi:10.2337/diabetes.54.11.3103 · Cited by 427
Hyperglycemia and the Pathobiology of Diabetic Complications
Aronson, D. (2008) · Advances In Cardiology · doi:10.1159/000115118 · Cited by 362
Miyata, T., Wada, Y., Cai, Z., Iida, Y., Horie, K., Yasuda, Y., Maeda, K., Kurokawa, K., & De Strihou, C. V. Y. (1997) · Kidney International · doi:10.1038/ki.1997.160 · Cited by 352
Glycation impairs high-density lipoprotein function
Hedrick, C. C., Thorpe, S. R., Fu, M.-X., Harper, C. M., Yoo, J., Kim, S.-M., Wong, H., & Peters, A. L. (2000) · Diabetologia · doi:10.1007/s001250050049 · Cited by 310
Miyata, T., van Ypersele de Strihou, C., Ueda, Y., Ichimori, K., Inagi, R., Onogi, H., Ishikawa, N., Nangaku, M., & Kurokawa, K. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000032418.67267.f2 · Cited by 290
Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging
Thorpe, S. R., & Baynes, J. W. (1996) · Drugs & Aging · doi:10.2165/00002512-199609020-00001 · Cited by 285
Forbes, J. M., Thallas, V., Thomas, M. C., Founds, H. W., Burns, W. C., Jerums, G., & Cooper, M. E. (2003) · The FASEB Journal · doi:10.1096/fj.02-1102fje · Cited by 263
SUZUKI, D., MIYATA, T., SAOTOME, N., HORIE, K., INAGI, R., YASUDA, Y., UCHIDA, K., IZUHARA, Y., YAGAME, M., SAKAI, H., et al. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v104822 · Cited by 254
Wendt, T., Tanji, N., Guo, J., Hudson, B. I., Bierhaus, A., Ramasamy, R., Arnold, B., Nawroth, P. P., Yan, S. F., D’Agati, V., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065100.17349.ca · Cited by 239
Renal catabolism of advanced glycation end products: the fate of pentosidine
Miyata, T., Ueda, Y., Horie, K., Nangaku, M., Tanaka, S., de Strihou, C. V. Y., & Kurokawa, K. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00756.x · Cited by 227
“Advanced glycation end product levels increase mildly with age, more markedly in diabetes [12, 13], and dramatically in uremia with or without diabetes [14–16].”
BackgroundHorie, K., Miyata, T., Yasuda, T., Takeda, A., Yasuda, Y., Maeda, K., Sobue, G., & Kurokawa, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6944 · Cited by 137
Kidney, heart and brain: three organs targeted by ageing and glycation
Frimat, M., Daroux, M., Litke, R., Nevière, R., Tessier, F. J., & Boulanger, E. (2017) · Clinical Science · doi:10.1042/cs20160823 · Cited by 88
Pentosidine and N-Carboxymethyl-Lysine: Biomarkers for Type 2 Diabetic Retinopathy
Ghanem, A. A., Elewa, A., & Arafa, L. F. (2011) · European Journal of Ophthalmology · doi:10.5301/ejo.2010.4447 · Cited by 73
Metadata
- Authors
- Beisswenger, P. J., Moore, L. L., Brinck-Johnsen, T., & Curphey, T. J.
- Venue
- Journal of Clinical Investigation
- Published
- 1993-07-01
- Volume
- 92
- Issue
- 1
- Pages
- 212-217
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2099486635
- Cited by
- 172
- References
- 0
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.